RecruitingPHASE1, PHASE2NCT05417932

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

Studying Combined hepatocellular carcinoma and cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
SCG Cell Therapy Pte. Ltd.
Principal Investigator
SCG Cell Therapeutics
SCG Cell Therapy Pte. Ltd.
Intervention
SCG101(biological)
Enrollment
46 target
Eligibility
18-70 years · All sexes
Timeline
20222025

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05417932 on ClinicalTrials.gov

Other trials for Combined hepatocellular carcinoma and cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma

← Back to all trials